Daniel Ciccarone, MD, MPH

Title(s)Professor, Family Community Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine
    UC BerkeleyM.P.H.1998Public Health
    SUNY Stony BrookM.D.1987School of Medicine
    Collapse Awards and Honors
    UCSF2014Chancellor’s Advisory Committee on Sustainability: Annual Sustainability Faculty Award
    UCSF School of Medicine2009Essential Core Teaching Award, Outstanding Lecture (class of 2011)
    UCSF School of Medicine2006Essential Core Teaching Award, Outstanding FPC Facilitator
    UCSF2005Elected, Academy of Medical Educators

    Collapse Overview 
    Collapse Overview
    My research is centered on the contextual issues of treatment and prevention of HIV/AIDS, and related diseases, in socially marginalized populations. My long-term objective is to combine ethnographic and epidemiological research to explore the intricate socio-behavioral-medical issues of medication adherence, access to care and risk taking behaviors, particularly related to drug use and drug users. My work, including collaborations, has been published in JAMA, NEJM, PLoS Medicine, AJPH, JAIDS and other peer-reviewed journals.

    My recent research is in exploring the different medical consequences of use of various sources and forms of heroin. The US has recently entered a new heroin epidemic, this time fueled by the recent opioid pill epidemic. My team is exploring the economic, anthropological, historical, clinical and public health dimensions of this crisis.

    In my activities as a medical educator, I have largely worked towards improving the social, behavioral and prevention science content within the undergraduate medical school curriculum. In 2009, I became Co-Director for the Foundations of Patient Care (FPC) course. In this role, I design and administrate FPC during the Organs Block of the Essential Core course. I am also Director of the Transitional Clerkship, a two-week immersion into the clinical wards for finishing second year medical students transitioning to their clinical training years. In these roles, I am responsible for designing extensive curricula, editing syllabi, recruiting faculty, hosting sessions and direct teaching, as well as, designing and leading assessment activities.

    Collapse Research 
    Collapse Research Activities and Funding
    Heroin in Transition
    NIH/NIDA R01DA037820Mar 15, 2015 - Jan 31, 2020
    Role: Principal Investigator
    Heroin Price, Purity and Outcomes Study
    NIH/NIDA R01DA027599Mar 15, 2010 - Jan 31, 2015
    Role: Principal Investigator
    The Medical Consequences of Different Types of Heroin
    NIH/NIDA K23DA016165May 1, 2004 - Apr 30, 2010
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Global Health
    Collapse Websites
    Collapse In The News
    Collapse Featured Presentations
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Mars SG, Rosenblum D, Ciccarone D. Fentanyl: the many challenges ahead. Addiction. 2019 Mar 15. PMID: 30873700.
      View in: PubMed
    2. Ciccarone D. Heroin Smoking Is Not Common in the United States. JAMA Neurol. 2019 Mar 11. PMID: 30855649.
      View in: PubMed
    3. Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019 Feb 01. PMID: 30718120.
      View in: PubMed
    4. Mars SG, Rosenblum D, Ciccarone D. Illicit fentanyls in the opioid street market: desired or imposed? Addiction. 2018 Dec 04. PMID: 30512204.
      View in: PubMed
    5. Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2018 Oct 03. PMID: 30292493.
      View in: PubMed
    6. Harris M, Brathwaite R, Scott J, Gilchrist G, Ciccarone D, Hope V, McGowan CR. Drawing attention to a neglected injecting-related harm: a systematic review of AA amyloidosis among people who inject drugs. Addiction. 2018 Oct; 113(10):1790-1801. PMID: 29697879.
      View in: PubMed
    7. Mars SG, Ondocsin J, Ciccarone D. Toots, tastes and tester shots: user accounts of drug sampling methods for gauging heroin potency. Harm Reduct J. 2018 05 16; 15(1):26. PMID: 29769132.
      View in: PubMed
    8. Dasgupta N, Beletsky L, Ciccarone D. Opioid Crisis: No Easy Fix to Its Social and Economic Determinants. Am J Public Health. 2018 Feb; 108(2):182-186. PMID: 29267060.
      View in: PubMed
    9. Mars SG, Ondocsin J, Ciccarone D. Sold as Heroin: Perceptions and Use of an Evolving Drug in Baltimore, MD. J Psychoactive Drugs. 2018 Apr-Jun; 50(2):167-176. PMID: 29211971.
      View in: PubMed
    10. Ciccarone D. Fentanyl in the US heroin supply: A rapidly changing risk environment. Int J Drug Policy. 2017 08; 46:107-111. PMID: 28735776.
      View in: PubMed
    11. Ciccarone D, Ondocsin J, Mars SG. Heroin uncertainties: Exploring users' perceptions of fentanyl-adulterated and -substituted 'heroin'. Int J Drug Policy. 2017 08; 46:146-155. PMID: 28735775.
      View in: PubMed
    12. Unick GJ, Ciccarone D. US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations. Int J Drug Policy. 2017 08; 46:112-119. PMID: 28688539.
      View in: PubMed
    13. Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. The Textures of Heroin: User Perspectives on "Black Tar" and Powder Heroin in Two U.S. Cities. J Psychoactive Drugs. 2016 Sep-Oct; 48(4):270-8. PMID: 27440088.
      View in: PubMed
    14. Ciccarone D, Unick GJ, Cohen JK, Mars SG, Rosenblum D. Nationwide increase in hospitalizations for heroin-related soft tissue infections: Associations with structural market conditions. Drug Alcohol Depend. 2016 06 01; 163:126-33. PMID: 27155756; PMCID: PMC4881875 [Available on 06/01/17].
    15. Ciccarone D, Bourgois P. Injecting drugs in tight spaces: HIV, cocaine and collinearity in the Downtown Eastside, Vancouver, Canada. Int J Drug Policy. 2016 07; 33:36-43. PMID: 27117187; PMCID: PMC4947565 [Available on 07/01/17].
    16. Mars SG, Fessel JN, Bourgois P, Montero F, Karandinos G, Ciccarone D. Heroin-related overdose: The unexplored influences of markets, marketing and source-types in the United States. Soc Sci Med. 2015 Sep; 140:44-53. PMID: 26202771; PMCID: PMC4587985.
    17. Ciccarone D, Harris M. Fire in the vein: Heroin acidity and its proximal effect on users' health. Int J Drug Policy. 2015 Nov; 26(11):1103-10. PMID: 26077143.
      View in: PubMed
    18. Unick G, Rosenblum D, Mars S, Ciccarone D. The relationship between US heroin market dynamics and heroin-related overdose, 1992-2008. Addiction. 2014 Nov; 109(11):1889-98. PMID: 24938727.
      View in: PubMed
    19. Rosenblum D, Castrillo FM, Bourgois P, Mars S, Karandinos G, Unick GJ, Ciccarone D. Urban segregation and the US heroin market: a quantitative model of anthropological hypotheses from an inner-city drug market. Int J Drug Policy. 2014 May; 25(3):543-55. PMID: 24445118; PMCID: PMC4062603.
    20. Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. "Every 'never' I ever said came true": transitions from opioid pills to heroin injecting. Int J Drug Policy. 2014 Mar; 25(2):257-66. PMID: 24238956; PMCID: PMC3961517.
    21. Rosenblum D, Unick GJ, Ciccarone D. The entry of Colombian-sourced heroin into the US market: the relationship between competition, price, and purity. Int J Drug Policy. 2014 Jan; 25(1):88-95. PMID: 24211155; PMCID: PMC3946788.
    22. Messac L, Ciccarone D, Draine J, Bourgois P. The good-enough science-and-politics of anthropological collaboration with evidence-based clinical research: Four ethnographic case studies. Soc Sci Med. 2013 Dec; 99:176-86. PMID: 23664236; PMCID: PMC3775979.
    23. Unick GJ, Rosenblum D, Mars S, Ciccarone D. Intertwined epidemics: national demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993-2009. PLoS One. 2013; 8(2):e54496. PMID: 23405084; PMCID: PMC3566161.
    24. Ciccarone D. Saying goodbye to high-dead-space syringes. Int J Drug Policy. 2013 Jan; 24(1):15-6. PMID: 23127666.
      View in: PubMed
    25. Ciccarone D, Yu T, Nye H, Chang A. A technology-enhanced medical note-writing workshop. Med Educ. 2012 Nov; 46(11):1121-2. PMID: 23078711.
      View in: PubMed
    26. Hettema JE, Ratanawongsa N, Manuel JK, Ciccarone D, Coffa D, Jain S, Lum PJ. A SBIRT curriculum for medical residents: development of a performance feedback tool to build learner confidence. Subst Abus. 2012; 33(3):241-50. PMID: 22738001; PMCID: PMC3412302.
    27. Ciccarone D.Review of The World Heroin Market: Can Supply Be Cut? (Oxford, 2009) by Letizia Paoli, Victoria A. Greenfield and Peter Reuter. Asian Journal of Criminology. 2012; 7(1):95-97.
    28. Ciccarone D. Henceforth harm reduction? Int J Drug Policy. 2012 Jan; 23(1):16-7. PMID: 21852090; PMCID: PMC3691071.
    29. Ciccarone D. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Prim Care. 2011 Mar; 38(1):41-58. PMID: 21356420.
      View in: PubMed
    30. Ciccarone D, Unick GJ, Kraus A. Impact of South American heroin on the US heroin market 1993-2004. Int J Drug Policy. 2009 Sep; 20(5):392-401. PMID: 19201184; PMCID: PMC2719678.
    31. Ciccarone D. Heroin in brown, black and white: structural factors and medical consequences in the US heroin market. Int J Drug Policy. 2009 May; 20(3):277-82. PMID: 18945606; PMCID: PMC2704563.
    32. Ciccarone D, Jain S, Bourgois P. Understanding illicit substance use in the real world. Med Educ. 2008 May; 42(5):532. PMID: 18412911; PMCID: PMC2597378.
    33. Hoffman A, Utley B, Ciccarone D. Improving medical student communication skills through improvisational theatre. Med Educ. 2008 May; 42(5):537-8. PMID: 18412916; PMCID: PMC2597306.
    34. Gilbert P, Ciccarone D, Gansky SA, Bangsberg DR, Clanon K, McPhee SJ, Calderón SH, Bogetz A, Gerbert B. Interactive "Video Doctor" counseling reduces drug and sexual risk behaviors among HIV-positive patients in diverse outpatient settings. PLoS One. 2008 Apr 23; 3(4):e1988. PMID: 18431475.
      View in: PubMed
    35. Cooper HL, Brady JE, Ciccarone D, Tempalski B, Gostnell K, Friedman SR. Nationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditis. Clin Infect Dis. 2007 Nov 01; 45(9):1200-3. PMID: 17918083; PMCID: PMC2567828.
    36. Mannheimer SB, Mukherjee R, Hirschhorn LR, Dougherty J, Celano SA, Ciccarone D, Graham KK, Mantell JE, Mundy LM, Eldred L, Botsko M, Finkelstein R. The CASE adherence index: A novel method for measuring adherence to antiretroviral therapy. AIDS Care. 2006 Oct; 18(7):853-61. PMID: 16971298; PMCID: PMC2567829.
    37. Bourgois P, Martinez A, Kral A, Edlin BR, Schonberg J, Ciccarone D. Reinterpreting ethnic patterns among white and African American men who inject heroin: a social science of medicine approach. PLoS Med. 2006 Oct; 3(10):e452. PMID: 17076569; PMCID: PMC1621100.
    38. Duru OK, Collins RL, Ciccarone DH, Morton SC, Stall R, Beckman R, Miu A, Kanouse DE. Correlates of sex without serostatus disclosure among a national probability sample of HIV patients. AIDS Behav. 2006 Sep; 10(5):495-507. PMID: 16779659; PMCID: PMC2567832.
    39. Gerbert B, Danley DW, Herzig K, Clanon K, Ciccarone D, Gilbert P, Allerton M. Reframing "prevention with positives": incorporating counseling techniques that improve the health of HIV-positive patients. AIDS Patient Care STDS. 2006 Jan; 20(1):19-29. PMID: 16426152.
      View in: PubMed
    40. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, Downing M, Edlin BR. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005 Jun; 82(2):303-11. PMID: 15872192; PMCID: PMC2570543.
    41. Kral AH, Lorvick J, Ciccarone D, Wenger L, Gee L, Martinez A, Edlin BR. HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco. J Urban Health. 2005 Mar; 82(1 Suppl 1):i43-50. PMID: 15738321; PMCID: PMC3456175.
    42. Schackman BR, Finkelstein R, Neukermans CP, Lewis L, Eldred L, Ciccarone D et al.The cost of HIV medication adherence support interventions: Results of a cross-site evaluation. AIDS Care. 2005; 17(8):927-37.
    43. Ciccarone D.The Political Economy of Heroin: Regional Markets, Practices and Consequences. Int J Drug Policy. 2005; 16(5):289-90.
    44. Ciccarone D, Coffin P, Preer G. Integrating HIV risk reduction into the medical curriculum. Med Educ. 2004 Nov; 38(11):1197-8. PMID: 15507033; PMCID: PMC2579263.
    45. Charlebois ED, Perdreau-Remington F, Kreiswirth B, Bangsberg DR, Ciccarone D, Diep BA, Ng VL, Chansky K, Edlin BR, Edlin B, Chambers HF. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2004 Jul 01; 39(1):47-54. PMID: 15206052; PMCID: PMC2567833.
    46. Ciccarone D, Bourgois P. Explaining the geographical variation of HIV among injection drug users in the United States. Subst Use Misuse. 2003 Dec; 38(14):2049-63. PMID: 14677781; PMCID: PMC1343535.
    47. Ciccarone DH, Kanouse DE, Collins RL, Miu A, Chen JL, Morton SC, Stall R. Sex without disclosure of positive HIV serostatus in a US probability sample of persons receiving medical care for HIV infection. Am J Public Health. 2003 Jun; 93(6):949-54. PMID: 12773361; PMCID: PMC1447876.
    48. Seal KH, Downing M, Kral AH, Singleton-Banks S, Hammond JP, Lorvick J, Ciccarone D, Edlin BR. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. J Urban Health. 2003 Jun; 80(2):291-301. PMID: 12791805; PMCID: PMC3456285.
    49. Ciccarone D.With Both Eyes Open: Notes on a Disciplinary Dialogue between Ethnographic and Epidemiological Research among Injection Drug Users. Int J Drug Policy. 2003; 14(1):115-8.
    50. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001 Jul 19; 345(3):211-5. PMID: 11463019; PMCID: PMC1510901.
    51. Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, Edlin BR. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis. 2001 Jul 01; 33(1):35-40. PMID: 11389492.
      View in: PubMed
    52. Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, Moss A. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001 Apr 15; 26(5):435-42. PMID: 11391162.
      View in: PubMed
    53. Ciccarone D, Bamberger J, Kral A, Hobart CJ, Moon A, Edlin BR, Harris HW, Young DM, Bourgois P, Murphy EL.Soft Tissue Infections Among Injection Drug Users - San Francisco, California, 1996-2000. JAMA. 2001; 285(21):2707-2709.
    54. Lurie P, Avins AL, Phillips KA, Kahn JG, Lowe RA, Ciccarone D. The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infection. JAMA. 1994 Dec 21; 272(23):1832-8. PMID: 7990217.
      View in: PubMed
    55. Phillips KA, Lowe RA, Kahn JG, Lurie P, Avins AL, Ciccarone D. The cost-effectiveness of HIV testing of physicians and dentists in the United States. JAMA. 1994 Mar 16; 271(11):851-8. PMID: 8114240.
      View in: PubMed
    56. Lurie P, Lowe RA, Avins AL, Phillips KA, Kahn JG, Franks PE, Ciccarone DH. Undiagnosed HIV infection in acute care hospitals. N Engl J Med. 1992 Dec 17; 327(25):1815-6. PMID: 1435939.
      View in: PubMed